Read Larry Connors' blog – Short Term Trading Strategies
Full year revenue for 2008 is expected to be approximately $5.35 billion. In addition, based on initial submissions, the Company finished the year with more than $360 million of cash on the balance sheet. Accordingly, the Company anticipates that its leverage ratio for bank purposes at December 31, 2008 will be approximately 3.7 times.
What They Do: Jarden Corporation is a leading provider of niche consumer products. Jarden operates in three primary business segments through a number of well recognized brands.
How They Trade: JAH has a 52 week high of $27.93 and a 52 week low of $7.20.
Iconix Brand Group (Nasdaq: ICON) Closed at $9.78. Today announced that Target Corporation (NYSE: TGT) has renewed its direct-to-retail license agreement for Iconix's Mossimo brand through January 31, 2012. Mossimo has been licensed exclusively to Target in the U.S. since 2000.
What They Do: Iconix Brand Group, Inc. (Nasdaq: ICON) owns, licenses and markets a growing portfolio of consumer brands including CANDIE'S , BONGO , BADGLEY MISCHKA , JOE BOXER , RAMPAGE , MUDD , LONDON FOG , MOSSIMO , OCEAN PACIFIC , DANSKIN , ROCA WEAR , CANNON , ROYAL VELVET , FIELDCREST , CHARISMA , STARTER and WAVERLY .
How They Trade: ICON has a 52 week high of $22.80 and a 52 week low of $5.11.
Synta Pharmaceuticals Corp. (Nasdaq: SNTA) Closed at $6.45 andRoche (SWX: ROG), Today announced the formation of a strategic alliance to discover, develop, and commercialize small-molecule drugs targeting a novel family of ion channels that are critical to immune cell function, known as calcium release-activated calcium modulator (CRACM) channels.
In preclinical models, the CRACM inhibitors discovered by Synta potently and selectively inhibit the secretion of pro-inflammatory factors such as TNF-alpha and IL-2, with minimal effects on other cells or signaling pathways. This program represents a new category of oral, targeted, disease-modifying agents for treating rheumatoid arthritis and a broad range of other inflammatory diseases.
What They Do: Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small-molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases.
How They Trade: SNTA has a 52 week high of $10.30 and a 52 week low of $4.29.
Clean Diesel Technologies (Nasdaq: CDTI) Closed at $2.78. Today announced along with Eaton Corporation (NYSE: ETV) that they have entered into a global non-exclusive licensing agreement. Under the agreement, Eaton will use Clean Diesel's patented Advanced Reagent Injector System (ARIS(r)) technology for injection of hydrocarbon fuel in emissions reduction applications, including Eaton's Aftertreatment System. This technology can also be applied to regeneration of diesel particulate filters and lean NOx traps in various global applications.
What They Do: Clean Diesel Technologies is a cleantech company providing sustainable solutions to reduce emissions, increase energy efficiency and lower the carbon intensity of on- and off-road engine applications.
How They Trade: CDTI has a 52 week high of $23.55 and a 52 week low of $1.54.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com has been a leading site for news on small-cap stocks since 1999. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select small-cap stocks, to register visit http://www.smallcapreview.com/subscribe.htm
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
15260 Ventura Blvd., Ste. 2200
Sherman Oaks, CA 91403
© Copyright 2009 The Connors Group, Inc.
